Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

In development
Reference number: GID-TA11963
Expected publication date: 13 January 2027

Documents

Documents created during the development process.

Invitation to participate

Final scope (PDF 143 KB)

Published:

10 April 2026
Final stakeholder list (PDF 147 KB)

Published:

10 April 2026
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 237 KB)

Published:

10 April 2026
Equality impact assessment (scoping) (PDF 113 KB)

Published:

10 April 2026

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 162 KB)

Published:

19 February 2026
Draft matrix of consultees and commentators post referral (PDF 147 KB)

Published:

19 February 2026